{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-006564","form_type":"8-K","ticker":"ARDX","cik":"0001437402","company_name":"ARDELYX, INC.","filed_at":"2025-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.627232+00:00","generated_at":"2026-05-26T08:28:53.334841+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ardelyx reports FY2024 revenue $333.6M; narrows net loss to $39.1M; provides 2025 guidance","bullets":["Total revenue $333.6M in 2024, up from $124.5M in 2023; driven by IBSRELA ($158.3M) and XPHOZAH ($160.9M) sales.","Net loss narrowed to $39.1M ($0.17 per share) from $66.1M ($0.30 per share) in 2023.","Cash and investments ended at $250.1M; drew $49.7M under term loan in Q4 2024.","IBSRELA 2025 net sales guidance: $240–250M; reaffirmed peak combined sales potential of $1.75B.","SG&A expenses rose to $258.7M from $134.4M due to sales team expansion and XPHOZAH launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-006564","json":"https://secwatch.observer/filing/0001628280-25-006564.json","markdown":"https://secwatch.observer/filing/0001628280-25-006564.md","text":"https://secwatch.observer/filing/0001628280-25-006564.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437402/000162828025006564/0001628280-25-006564-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437402/000162828025006564/ardx-20250220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T08:28:53.334841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}